INTRODUCTION
Lysosomal enzymes are synthesized on the rough endoplasmic reticulum and are co-translationally transported into the lumen of the endoplasmic reticulum. After cleavage of the signal peptide and the acquisition of N-linked oligosaccharide side chains lysosomal enzymes are transported to the Golgi apparatus. Whereas secretory proteins pass the Golgi apparatus, lysosomal enzymes specifically acquire mannose-6-phosphate residues, which serve as a lysosomal targetting signal (for a detailed review see [1] ). In a late Golgi compartment these residues bind to mannose-6-phosphate receptors (M6PRs), which mediate further vesicular transport to the lysosomes. Upon acidification in a prelysosomal compartment, lysosomal enzymes dissociate from the receptors and are delivered to the lysosomes, whereas free receptors recycle. Synthesis of mannose 6-phosphate requires two enzymic reactions: a phosphotransferase (UDP-Nacetylglucosamine lysosomal enzyme N-acetylglucosaminephosphotransferase, EC 2.7.8.17) transfers glucosamine 1-phosphate from UDP-N-acetylglucosamine to mannose residues ofthe high-mannose-type oligosaccharide side chains oflysosomal enzymes, creating N-acetylglucosamine-l-phospho-6-mannose residues. In a second reaction N-acetylglucosamine is removed by an a-N-acetylglucosaminidase, which generates the mannose-6-phosphate residues on lysosomal enzymes. Five different mannose residues within an oligosaccharide side chain can be phosphorylated but not more than two in a single oligosaccharide. A critical step in the sorting of lysosomal enzymes is the recognition by phosphotransferase. Insights into the mechanism of phosphorylation have come from two genetic diseases: mucolipidosis II and III. Both diseases are caused by the inability of the cells to synthesize the mannose-6-phosphate recognition marker. This leads to enhanced secretion of lysosomal enzymes, which results in a multiple intracellular deficiency. The disease is caused by deficiency of the phosphotransferase and two major complementation groups have been found [2] . Complementation studies, as well as biochemical studies, revealed enzymic activity nor with pH-dependent dimerization of ASA. The epitopes recognized by the antibodies have been located in the second quarter of the ASA polypeptide using chimeric mouse-human ASA molecules. Three of the monoclonal antibodies bind to identical or closely adjacent epitopes, which are formed by the interaction of amino acid residues 165-184 and 202-240. The fourth antibody recognizes a different epitope within amino acids 256-265. that the phosphotransferase is composed of at least two subunits. One subunit may be involved in the recognition of lysosomal enzymes, whereas the other catalyses the transfer of Nacetylglucosamine 1-phosphate to mannose residues of the oligosaccharide side chains (see [2] for further references).
No obvious sequence similarities are detectable among lysosomal enzymes. The phosphotransferase recognition domain is therefore assumed to be a motif depending on the threedimensional structure of lysosomal enzymes. It has been demonstrated that denatured lysosomal enzymes are not recognized by the phosphotransferase [3] . Recently, sequences involved in the recognition have been characterized in the lysosomal aspartyl protease cathepsin D [4] . This approach has used chimeric molecules constructed of different parts of cathepsin D and the homologous non-lysosomal zymogen pepsinogen. By introduction of different parts of cathepsin D into the pepsinogen background, the latter could be converted into a substrate of the phosphotransferase and was targetted to lysosomes via the M6PR pathway. To achieve this a sequence of 27 amino acid residues near the C-terminus of cathepsin D and a single lysine had to be introduced into the pepsinogen cDNA. The lysine was located in an area which, in the linear sequence, was not contiguous to the 27-amino-acid cathepsin D fragment. Crystallographic data from the pepsinogen, and recently from the cathepsin D molecule [5] , allowed the conclusion that the sequences around the lysine residue and the sequences of the 27-amino-acid fragment are in proximity on the surface of the correctly folded enzyme. Although this represents the first characterization of a lysosomal topogenic signal, it is still unknown to what extent it is shared by other lysosomal enzymes.
Arylsulphatase A (ASA, EC 3.1.6.8) is a lysosomal enzyme, which is sorted via the M6PR pathway [6] . This [35S]Methionine (specific radioactivity > 600 Ci/mmol) and [y-32P]ATP (specific radioactivity > 3000 Ci/mmol) was purchased from Amersham. The anti-ASA polyclonal antiserum was raised in goat and has been described previously [7] . Rhodamine-coupled anti-(mouse IgG) used for immunofluorescent staining were obtained from Sigma (Deisenhofen, Germany). Horseradish peroxidase-coupled goat anti-(mouse IgG) was from Medac (Hamburg, Germany). Immunoglobulin isotypes were determined with a kit from Paesel and Lorei (Frankfurt, Germany). Baby hamster kidney (BHK) cell lines stably transfected with cDNAs of ASA [9] , arylsulphatase B (ASB; EC 3.1.6.12) [10] Purfflcation of ASA and ASB ASA was purified from human liver by a procedure which has been described previously [12] . Briefly, 1 Peritoneal macrophages isolated from mice were used as feeders.
Selection of hybridomas was started after 1 week by the addition of selection medium containing 100 lOM hypoxanthine, 16 ,uM thymidine, and 0.4 ,uM aminopterine [14] . A Immunoprecipitation and metabolic labelling BHK cells overexpressing the ASA cDNA were grown to confluency and harvested with trypsin. The cell pellet was washed with PBS/0. 1% fetal-calf serum to remove trypsin and homogenized by three 15 s bursts of sonication in 2 ml of H20. Hybridoma supernatants were dialysed against 50 mM Tris/HCl (pH 8.0)/0.15 M NaCl/0.05 % Triton X-l00. A sample (14 pul) of BHK cell homogenate containing 5 m-units of ASA was mixed with 100 jul of dialysed hybridoma supernatant and 10 jug of goat anti-(mouse IgG) serum was added. After incubation for 30 min at room temperature and 16 h at 4°C immunoglobulins were collected by incubation for 2 h with 60 jul of Pansorbin (Calbiochem). Bacteria were pelleted, washed once and ASA activity was determined in the pellets and in the supernatants.
The immunoprecipitation procedure for ASA from homogenates of metabolically labelled cells has been described in detail [6] . In the experiments described here the protocol was modified as follows: before preabsorption of cell homogenates with Staphylococcus aureus bacteria the DNA was removed by precipitation with protamine sulphate. The homogenate was adjusted to 0.030% protamine sulphate and kept on ice for Immunocomplexes were allowed to bind for 2 h at 4 'C. Collection and washing of immunoprecipitates has been described [6] .
Indirect immunofluorescence Cells were grown at low density on glass coverslips (104 cells/coverslip). Cells were washed with PBS, and fixed with removed and coverslips were washed three times with PBS/0.2 % gelatin before a 1:200 dilution of the second antibody ([anti-(mouse IgG) raised in rabbit and coupled with rhodamine] was added. The antibody was allowed to bind for 1 h at room temperature and after washing the coverslips were mounted on glass slides.
Western-blot analysis Aliquots containing 500 ng ofASA were applied to an SDS/7.5 % (w/v) polyacrylamide gel. The gel was electroblotted in 25 mM glycine/25 mM ethanolamine/20% 0 (v.v) methanol at 4°C at SDS/polyacrylamide gel was stained afterwards with Coomassie Blue. The nitrocellulose membrane was incubated at 4°C overnight with 5 % (w/v) milk powder/0.05 % Triton X-100 in PBS to block unspecific binding. The membrane was cut into strips according to the lanes of the SDS/polyacrylamide gel and these strips were incubated with different antibodies in the buffer mentioned above. For controls a 1:100 dilution of polyclonal antiserum was used. Hybridoma supernatants were concentrated up to 5-fold and dialysed against PBS; ascites were diluted 1:100. Incubation with antibodies was for 5 h at room temperature. Strips were washed for 2 x 20 min and 2 x 5 min at room temperature with PBS to remove unbound antibody. For the detection ofASA-bound antibodies a horseradish peroxidasecoupled anti-(mouse IgG) antibody was added for 2 h. After washing the strips were developed for up to 1 h at room temperature.
Phosphorylation of ASA in vitro Golgi membranes were prepared from male Sprague-Dawley rats obtained from the Tierzuchtanstalt Hannover. Animals were starved overnight and killed by decapitation the next morning. The liver was removed, cut into small pieces and homogenized three times for 30 s in a Braun Melsungen glass homogenizer (S502) at low speed in 3 ml of 0.5 M sucrose/5 mM MgCl2/50 mM Tris/HCl (pH 7.4) for each gram of liver tissue. Debris was removed by centrifugation at 6000 g for 10 min at 4 'C. Supernatant was recovered and adjusted to 0.17 unit/ml aprotinin. Supernatant (38 ml) was layered on to the top of a 20 ml 1.3 M sucrose cushion and centrifuged for 2 h at 25000 rev./min (90000 g) in an SW 25.2 rotor (Beckman). The membrane layer on top of the 1.3 M sucrose was removed and adjusted to 1.1 M sucrose by determination of the refraction index. A sample (27 ml) of this solution was overlayed with 7 ml of 1 M sucrose and 5 ml of 0.5 M sucrose and centrifuged for 30 min at 25000 rev./min (120000g) in an SW 28.1 rotor (Beckman). The Golgi-membrane fraction appeared as a white band at the border of the 0.5 M and 1.0 M sucrose layer. This fraction was collected and adjusted to 0.25 M sucrose and 0.4 M NaCl. Membranes were pelleted at 45000 rev./min (200000 g) for 45 min in a Ti *60 rotor (Beckman). The pellet was resuspended in water and stored at -20 'C. Protein yield was about 1.4 mg. For details of the procedure see [15] .
[/J-32P]UDP-N-acetylglucosamine was synthesized according to a procedure described by Lang and Kornfeld [16] . The yield of radioactivity was 30-70 % and specific radioactivity 3000-4500 Ci/mmol. For the in vitro phosphorylation reaction the specific radioactivity was adjusted to 3-4.5 Ci/mmol. The phosphorylation assay contained various amounts of ASA or ASB, 35 mM sodium phosphate (pH 6.7), 22 juM [/-32P]UDP-Nacetylglucosamine, 1 % Triton X-100, 2 mM ADP, 10 mM CDP choline, 5 mM dimercaptopropanol, 125 juM leupeptin and up to 7 jul of Golgi membranes in a final volume of 20 ju1 [17] . After incubation for various times 100 ug of BSA was added and the proteins were precipitated with 25 % (w/v) trichloroacetic acid. Pellets were washed with ethanol and subjected to SDS/PAGE. For quantification of phosphorylation the autoradiograph was quantified by densitometry or by determination of radioactivity in the eluted gel slices.
Construction of chimeric ASA molecules For the mapping of the epitopes chimeric mouse-human ASA molecules were constructed. For this purpose we made use of a PstI restriction site conserved between mouse and human ASA 300 mA for 4 h. To control for efficient transfer the (see Figure 5 ). In this case the C-terminal half of the human molecule was replaced with the respective mouse sequences (construct 1). In all other cases (constructs 2, 3 and 4) fragments of the mouse cDNA were amplified with oligonucleotides which introduced restriction sites that allowed direct cloning into the human cDNA. The constructs were cloned into the expression vector pBEH [6] and stably (construct 1 and 2) or transiently (construct 3 and 4) expressed in BHK cells.
Generation of Fab fragments
Fab fragments of mAbs were generated by digestion with papain following a protocol described in [14] . to 50 1l of ASA-containing solutions. After incubation for different times the reaction was stopped by the addition of 500 ,ul of 1 M NaOH and extinction was read at 515 nm. Activity towards the natural substrate cerebroside sulphate was measured by using a fluorescently labelled analogue of this lipid [18] . The reaction conditions were identical to those ofthe natural substrate except that 1 % (w/v) Triton X-100 was present. Lipids were extracted by chloroform/methanol and separated by t.l.c. and quantified as described previously [19] . Protein was determined either by the absorption at 280 nm or by the method of Lowry [20] . Silver staining of SDS/polyacrylamide gels was done by the protocol of Ansorge [21] . SDS/PAGE and fluorography have been described [22] .
RESULTS
Characterization of mouse anti-ASA mAbs In an initial experiment the four mAbs were used to precipitate ASA under non-denaturing conditions from extracts of BHK cells overexpressing the human ASA cDNA (BHK-ASA cells). Each of the four antibodies precipitated more than 90 % of ASA activity. The amount of ASA present in pellets when ASA mAbs were used for immunoprecipitation was comparable with that in the supernatant of the control 46 kDa anti-M6PR antibody indicating that the anti-ASA mAbs did not inhibit the enzymic activity of the enzyme (Table 1 ). In contrast, the polyclonal anti-ASA antiserum inhibited the enzyme by about 50 %. In a similar assay mouse ASA was immunoprecipitated from lysates of mouse Ltk-cells (see Table 1 ). The niAb I I B5 precipitated about half of the mouse ASA activity, whereas the other mAbs showed no cross-reactivity.
To determine the specificity of the four mAbs, BHK cells overexpressing human ASA, ASB or STS were metabolically labelled overnight with [35S]methionine and cell extracts were subjected to immunoprecipitation with the mAbs and polyclonal antisera specific for ASA, ASB or STS (see Figure 1) . The four mAbs precipitated only ASA but none of the homologous sulphatases.
To test whether the mAbs are suitable for immunofluorescence staining BHK-ASA cells were fixed with formaldehyde and permeabilized with Triton X-100. Fixed cells were incubated with hybridoma culture media and a second rhodamine-coupled antibody was used to visualize the mouse immunoglobulins. All mAbs gave the typical lysosomal granular perinuclear staining (results not shown).
To assay the reactivity of the mAbs towards denatured enzyme, ASA was subjected to SDS/PAGE and transferred on to a nitrocellulose membrane. The membranes were incubated with the polyclonal anti-ASA goat serum and hybridoma supernatants or ascites dilutions of the mAbs. Whereas the goat antiserum detected ASA polypeptides none of the mAbs gave a signal (results not shown). In an additional experiment '25M-labelled ASA was carboxymethylated with iodoacetic acid and the reactivity of modified ASA with mAbs was tested. None of the mAbs immunoprecipitated the carboxymethylated ASA polypeptides under the conditions that allowed the precipitation of ASA activity (results not shown).
p-Nitrocatecholsulphate as well as the natural substrate of ASA, cerebroside sulphate, was used to examine the influence of the mAbs on the enzymic activity of ASA. None of the antibodies inhibited the activity of the enzyme (results not shown).
mAbs inhibit the recognition of ASA by the phosphotransferase In the Golgi apparatus lysosomal enzymes are specifically recognized by a phosphotransferase which transfers N-acetylglucosamine 1-phosphate on to mannose residues of oligosaccharide side chains. Phosphorylation of ASA can be followed in vitro using solubilized Golgi membranes from rat liver ASA purified to homogeneity was phosphorylated in vitro and subjected to SDS/PAGE. The reaction was performed without additions or in the presence of a 10-fold molar excess of the four mAbs or an irrelevant anti-M6PR antibody. Either intact immunoglobulins (Ig) or Fab fragments were added. ASA is indicated by an arrow. In the experiment shown the anti-M6PR antibody seems to inhibit the phosphorylation. We have repeated this control reaction in a different set of experiments and found no inhibition (results not shown; see also controls in Figure 3 ). Therefore the reduced signal in the right-hand lane is due to technical mistakes in this particular experiment. antibodies cover the proteinaceous phosphotransferase-recognition domain of ASA or they cover the phosphate-accepting mannose residues. In the latter case ASA-mAb complexes can still bind to the phosphotransferase but phosphorylation is impossible. Binding ofthe phosphotransferase with the lysosomal enzyme would not be inhibited by the antibodies. To distinguish between these two possibilities a competition experiment was designed. ASB, a closely related lysosomal sulphatase, has a similar high affinity for the phosphotransferase. For both ASA and ASB a Km value of about 2 ,uM was determined. ASB was phosphorylated in vitro in the presence of ASA. The amounts of both enzymes were adjusted such that ASA inhibited the phosphorylation of ASB by about 50 (Figure 3) . We recognition of the phosphate-accepting mannose residues, addition of anti-ASA mAbs should not relieve the inhibitory effect of ASA on the phosphorylation of ASB. Figure 3 shows that in the presence of Fab fragments of the control anti-M6PR antibody ASA inhibits the phosphorylation of ASB by about 50 %. Upon addition of a 10-fold molar excess of anti-ASA mAbs the inhibitory effect of ASA is completely abolished, demonstrating that the ASA-Fab fragment complexes do not compete with the phosphorylation of ASB. We conclude that the mAbs inhibit the phosphorylation of ASA by covering the proteinaceous phosphotransferase-recognition domain of the enzyme.
Influence of the anti-ASA mAbs on the pH-dependent dimerization of ASA As the size of the Fab fragments is similar to that of ASA the inhibition of phosphorylation could result from a sterical hindrance even if the epitopes recognized by the mAbs are far away from the phosphotransferase-recognition site. We have therefore examined whether binding of the mAbs interferes with the pHdependent dimerization of ASA. At neutral pH ASA is a monomer, whereas it dimerizes at pH 4.5 [24] . Beads to which monomeric ASA had been covalently coupled were incubated Mapping of the epitope recognized by the four mAbs To identify the epitopes recognized by the four mAbs we have made use of the observation that these mAbs did not (19C2, 20B1 and 20D2) cross-react, or only weakly (1 1B5), with mouse ASA. We constructed chimeras of the mouse and human ASA cDNA and overexpressed those hybrid ASA molecules in BHK cells.
Cells were harvested 48 h after transfection and the mAbs were used to precipitate ASA activity from cell homogenates. The constructs made are summarized in Figure 4 . The reactivity with mAbs is indicated. Constructs 1 and 2 reacted with all mAbs, indicating that all epitopes are located between amino acid residues 143 and 280, which represents the second quarter of the molecule. Chimeras 3 and 4 were constructed to narrow down epitopes further. mAbs 19C2, 20B1 and 20D2 still precipitated about 50 % of construct 3 but failed to recognize construct 4. 1 lB5 showed full reactivity with all constructs, locating its epitope between amino acid residues 244 and 280.
In order to examine whether the mAbs recognize the same epitope we performed competition experiments. mAbs were precoated on to 96-well plates. Human ASA, preincubated with a 10-fold (see Table 3) Using the human and mouse ASA cDNA chimeras were constructed. The constructs were expressed in BHK cells, ASA was immunoprecipitated from cell extracts and enzyme activity was determined in the supernatants, as well as in the immunoprecipitated pellets. The bar represents the coding sequence, white parts are human sequences, hatched parts are mouse sequences. Potential Nglycosylation sites are indicated by q. The restriction sites used for fusion in the human ASA cDNA are indicated as well as the amino acid in the human ASA at which the fusion occurred. The Table on the right-hand side shows the reactivity of the mAbs with the respective construct on the left-hand side. + indicates that more than 90% of ASA activity was immunoprecipitable, (+) indicates that 50% was immunoprecipitable and -shows that the mAb precipitated less than 10% of enzyme activity. The amount of antibodies added was sufficient to ensure a complete precipitation of the equivalent amount of human ASA. 
DISCUSSION
The four mAbs described ( No cross-reactivity with the homologous sulphatases ASB and STS could be detected. When tested with mouse ASA three mAbs (19C2, 20B1, 20D2) showed no, and one (1lB5) only weak, reactivity with the mouse enzyme. Using chimeric molecules constructed from mouse and human ASA cDNAs the epitopes recognized by the four mAbs could be located in the second quarter of the molecule. When the amino acid residues 143-194 were replaced by mouse sequences antibodies 19C2, 20B1 and 20D2 lost their reactivity partially and precipitated only half of the enzyme activity. When in addition amino residues 194-244 were replaced by mouse sequences reactivity was lost completely. This gradual loss of reactivity indicated that sequences present between residues 143 and 194 and 194 and 244 interact to form the epitopes and thus have to be in close spatial proximity on the surface of the molecule. Antibody 1 IB5 cross-reacts weakly with the mouse ASA but retains full reactivity with all of the constructs, which demonstrates that the epitope locates to the region in between the SstII and PstI sites which correspond to amino acids 244-280. That antibody 1 1B5 recognizes an epitope that is different from that of the other antibodies is also supported by the data from the competition experiments. If data in Table 3 are read columnwise from left to right it shows that 1 1B5-ASA complexes bind more efficiently to precoated 19C2, 20B1 and 20D2 than they do to 1lB5. In all other cases mAb-ASA complexes bind better to 1 1B5 than to the other precoated antibodies. This is in accordance with the results obtained from the chimeric molecules.
Since human and mouse ASA sequences are highly homologous, epitopes can be defined more precisely by a comparison of both sequences (see Figure 5 ). Two (Asp216 --Gly and Glu239 -. Lys) involve changes of polarity. Since the amino acid substitutions are not clustered, the epitope can only be localized between residues 202 and 240. The fragment 244-280 recognized by the 11 B5 antibody shows four adjacent substitutions so the epitope may be located to residues 256-265. ASA can be phosphorylated in vitro by the lysosomal enzyme phosphotransferase and we examined whether Fab fragments of the mAbs interfere with the phosphorylation of ASA in vitro. Addition of a 10-fold molar excess of Fab fragments caused complete inhibition of phosphorylation. This inhibition may be due to two different effects. The binding of the Fab fragment could cover the phosphate-accepting mannose residues. As the epitopes map close to two potential N-glycosylation sites this may be a plausible explanation. On the other hand binding of the Fab fragment may interfere with the recognition of ASA by the phosphotransferase. To differentiate between the two possibilities we have performed competition experiments in which the phosphorylation of the homologous lysosomal sulphatase ASB was partially inhibited by ASA. The addition of Fab fragments led to a full restoration of ASB phosphorylation, indicating that in contrast with ASA the ASA-mAb complexes did not function as competitors. This strongly indicates that those complexes are not recognized by the phosphotransferase. Since all epitopes map to the same region of the molecule it is not surprising that each of the antibodies inhibited the phosphorylation. Since the gradual loss of reactivity of antibodies 19C2, 20B1, 20D2 in constructs 3 and 4 demonstrated a spatial interaction of non-adjacent amino acid residues the epitopes recognized by 1 lB5 and the other antibodies might be in even closer proximity than it appears from the linear amino acid sequence. Since none of the antibodies failed to inhibit phosphorylation we cannot exclude the possibility that the inhibition of phosphorylation is a rather unspecific effect due to sterical hindrance exerted by Fab fragments bound to a site distant from the phosphotransferase-recognition domain. However, at least two other functions of the ASA polypeptides were not affected by binding of the mAbs. One is the enzymic activity towards natural and artificial substrates and the other is the pH-dependent dimerization of ASA. The enzyme is a monomer at pH 7, but dimerizes at pH 4.5. This demonstrates that binding of the mAbs neither interfered with the accessibility of the active site nor with the domains mediating dimerization.
Studies in other systems have shown that binding of Fab fragments to pentapeptide epitopes can functionally dissect closely adjacent epitopes. An example is the characterization of peptide sequences of the cytoplasmic tail of the 46 kDa M6PR by microinjection of Fab fragments from polyclonal antibodies directed against pentapeptide fragments of the 52-amino-acid tail. In this example Fab fragments directed against the amino acid residues 38-42 did not interfere with signal-mediated trafficking of the receptor, whereas those directed against the pentapeptide 43-48 did [25] . Thus Fab fragments, which are large in comparison to the peptides they recognize, can functionally distinguish neighbouring sequences as short as pentapeptides.
The lysosomal protease cathepsin D is so far the only example in which sequences involved in the recognition by the phosphotransferase have been located [4] . The topogenic sequences of cathepsin D (amino acid residues 203 and 265-292) are located in the C-terminal quarter of the molecule. As already mentioned there are no obvious sequence similarities among lysosomal enzymes, nor do they show a common pattern of glycosylation.
Comparison of the cathepsin D and ASA data also reveals that the location of the topogenic domains is not conserved. Topogenic cathepsin D sequences are located in the C-terminal part, whereas those of ASA seem to reside in the N-terminal part of the molecule. This conclusion is supported by the comparison of amino acid sequences of lysosomal sulphatases having different functions [26] . It is reasonable to assume that the topogenic motif is conserved among homologous sulphatases. The degree of sequence similarity is higher in the N-terminal sequences of sulphatases, whereas towards the C-terminus sequences become more divergent. Thus it is likely that a common topogenic motif is encoded in the N-terminal part of the molecule.
It will be necessary to generate a broader panel of anti-ASA mAbs to define more precisely the signals involved in the recognition of ASA by the phosphotransferase. The results of this study have revealed the feasibility of this approach.
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